MACK
Merrimack Pharmaceuticals, Inc. [MACK] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
MACK Stock Summary
In the News
MACK Financial details
Company Rating
-
Market Cap
213.33M
Income
-1.01M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-151.41
Forward P/E
-
PEG
41.95
P/S
-427.7
P/B
10.12
P/C
-
P/FCF
-134.79
Quick Ratio
38.34
Current Ratio
39.14
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.07
EPS next Y
-
EPS next Q
-
EPS this Y
-24.91%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-14.36%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-7%
ROE
-7%
ROC
-0.11%
Gross Margin
200%
Oper. Margin
484%
Profit Margin
282%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
11.53-15.89
52W High
-
52W Low
-
RSI
-
Rel Volume
7.51
Avg Volume
122.79K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
1.426
-
-
Volatility
0.01%, 0.01%
Prev Close
-
Price
-
Change
-
Company Profile
- Volume Average 122.79K
- Market Capitalization 213.33M
- CEO Mr. Gary L. Crocker M.B.A.
- Headquarters Cambridge,MA,US
- IPO Date 2012-03-29
-
Website
https://www.merrimack.com 
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
